Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Fuller & Thaler Asset Management Inc.

Fuller & Thaler Asset Management Inc. boosted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 10.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,630,940 shares of the biotechnology company's stock after acquiring an additional 708,312 shares during the period. Exelixis accounts for about 1.0% of Fuller & Thaler Asset Management Inc.'s holdings, making the stock its 15th biggest position. Fuller & Thaler Asset Management Inc. owned approximately 2.67% of Exelixis worth $254,110,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB raised its stake in shares of Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 290 shares during the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of Exelixis by 4.9% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after acquiring an additional 330 shares during the period. Oregon Public Employees Retirement Fund raised its holdings in Exelixis by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after purchasing an additional 354 shares in the last quarter. Principal Securities Inc. lifted its position in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 373 shares during the period. Finally, V Square Quantitative Management LLC boosted its holdings in Exelixis by 37.3% in the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 425 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Oppenheimer lowered Exelixis from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Stifel Nicolaus boosted their price target on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research note on Wednesday, February 12th. JMP Securities reaffirmed a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a research note on Thursday, April 17th. Barclays raised their price target on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Finally, UBS Group restated an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $37.59.

Exelixis Trading Up 2.5 %

Shares of EXEL stock opened at $36.48 on Wednesday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.02. The company has a market capitalization of $10.21 billion, a PE ratio of 20.61, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The firm has a fifty day simple moving average of $36.53 and a 200-day simple moving average of $34.43.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 10,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total value of $388,000.00. Following the completion of the transaction, the executive vice president now directly owns 341,028 shares of the company's stock, valued at $13,231,886.40. This represents a 2.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares in the company, valued at $28,174,996.98. The trade was a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 in the last three months. 2.85% of the stock is owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.